ArticleJournal of orthopaedic surgery and research2025
Experimental study of radial extracorporeal shock wave therapy for periprosthetic osteolysis induced by wear particles.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radial Extracorporeal Shock Wave Therapy (rESWT) is applied as a conservative treatment modality in orthopedics, yet its effectiveness in addressing aseptic loosening of cementless joint prostheses remains unclear. Through animal experimentation, we have revealed that in a titanium particle-induced osteolysis rat model, rESWT intervention significantly increased periprosthetic bone density compared to untreated controls, concurrently reducing osteolytic lesion area and lowering serum IL-1β levels. Histological analyses demonstrated a relative decrease in osteoclast counts within the treatment group versus non-treated controls. These findings indicate that rESWT, through mechanisms involving anti-inflammatory actions and suppression of osteoclastogenesis, may serve as a non-invasive therapeutic strategy for preventing and managing periprosthetic bone loss, demonstrating clinical potential to delay or eliminate the necessity for revision surgeries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.